HPG Axis Failure: Understanding the Target Landscape

Male hypogonadism is defined by subnormal serum testosterone below 300 ng/dL combined with characteristic clinical symptoms — a threshold that marks dysfunction at one or more levels of the hypothalamic-pituitary-gonadal (HPG) axis. Two primary etiological categories drive distinct therapeutic strategies: primary (hypergonadotropic) hypogonadism, arising from testicular dysfunction with elevated LH and FSH, and secondary (hypogonadotropic) hypogonadism (HH), characterised by deficient gonadotropin secretion from hypothalamic or pituitary impairment, with low or inappropriately normal LH and FSH levels.

The molecular architecture of the HPG axis provides six distinct therapeutic entry points captured across patent filings and academic literature. The androgen receptor (AR) sits at the convergence of testosterone, DHT, and SARM pharmacology — mediating anabolic effects in muscle and bone while also driving androgenic effects in prostate, hair follicles, and skin. The LH/hCG receptor (LHCGR), expressed on Leydig cells, mediates testosterone biosynthesis and is the target of both injectable hCG and emerging oral thieno[2,3-d]pyrimidine-based allosteric agonists. The FSH receptor (FSHR) governs spermatogenesis and is the target of oral small-molecule agonists in preclinical development at Baylor College of Medicine.

The estrogen receptor and aromatase (CYP19A1) axis provides an indirect route: SERMs and aromatase inhibitors relieve estrogenic negative feedback on the hypothalamus and pituitary, disinhibiting LH and FSH secretion. The GnRH receptor is the target of pulsatile GnRH therapy for congenital hypogonadotropic hypogonadism (CHH). According to WHO classifications, the distinction between primary and secondary hypogonadism is fundamental to treatment selection, as exogenous testosterone replacement suppresses the HPG axis and eliminates spermatogenesis — making axis-stimulatory approaches essential for fertility-seeking men.

Oral Testosterone Formulations: From First-Pass Problem to Phase III Signal

Oral testosterone delivery has historically failed due to hepatic first-pass metabolism, but oral testosterone undecanoate (TU) circumvents this by exploiting lymphatic absorption — and the clinical data for its newest formulation represent the strongest near-term commercial signal in the male hypogonadism pipeline. TLANDO (oral testosterone undecanoate, 225 mg twice daily) achieved eugonadal testosterone levels over 24 days without dose titration in an open-label US multicenter trial of 95 hypogonadal men (NCT03242590), conducted at San Diego Sexual Medicine/Alvarado Hospital Medical Center.

The elimination of food-dependent administration is a clinically meaningful differentiator from earlier oral TU formulations. Earlier versions required co-ingestion with a fatty meal to ensure adequate lymphatic uptake, creating compliance barriers and pharmacokinetic variability. The TLANDO trial’s 24-day eugonadal achievement without titration addresses both limitations simultaneously.

“Oral TU co-administered with hCG in 107 IHH patients did not impair spermatogenesis relative to hCG alone — signalling that oral testosterone may be integrated into fertility-preserving regimens.”

A retrospective study from Tongji Hospital (Huazhong University of Science and Technology) evaluated oral TU supplementation in combination with hCG in 107 isolated hypogonadotropic hypogonadism (IHH) patients. The finding that co-administration did not impair spermatogenesis relative to hCG alone is strategically significant: it suggests oral TU could be integrated into fertility-preserving regimens for IHH patients with subtherapeutic testosterone response to gonadotropins alone — a combination niche not addressed by conventional injectable TRT.

Conventional formulations — gels, pellets, and injectables — carry documented risks of transference to partners, suppression of spermatogenesis, and non-physiological pharmacokinetics. These limitations, highlighted in reviews from Barnsley Hospital NHS Foundation Trust and the University of Miami Miller School of Medicine, provide the commercial rationale for improved oral delivery systems. According to FDA guidance on testosterone products, transference risk has been a regulatory concern since the approval of topical formulations — reinforcing the appeal of oral alternatives for regulators and patients alike.

SARMs: The IP-Active Modality With a Regulatory Gap

Selective androgen receptor modulators (SARMs) represent the most IP-active modality in the male hypogonadism drug pipeline, with multiple academic programs and at least one advanced commercial preclinical candidate — yet a clearly identified regulatory barrier separates the science from commercialisation. The core mechanism of SARM tissue selectivity is well-characterised: SARM-AR interactions produce helix 12 conformational states in the androgen receptor ligand-binding domain that differ from those induced by testosterone, enabling distinct coactivator and corepressor recruitment profiles across tissue types.

This conformational distinction allows SARMs to preferentially activate anabolic pathways in muscle and bone while minimising stimulation of the prostate, hair follicles, and skin — the androgenic side-effect profile that limits conventional TRT. GTx, Inc., the most prominently identified commercial SARM assignee in the dataset, describes SARMs as providing “anabolic benefit in the absence of androgenic effects on prostate, hair and skin.” Current GTx clinical development focuses on acute muscle wasting (sarcopenia, cancer cachexia), with late-onset hypogonadism as a secondary indication.

Ostarine (Enobosarm) and Ligandrol (LGD-4033), evaluated in preclinical ovariectomized rat models at the University of Veterinary Medicine Hannover, demonstrated significant muscle mass and physical function improvements at doses of 0.04–4 mg/kg/day. While this model targets postmenopausal conditions, the results are mechanistically relevant to hypogonadal male muscle wasting. The University of Utah School of Medicine’s landscape review notes that no FDA-approved SARM indications existed as of the reporting period — a status that, combined with the absence of defined clinical endpoints for late-onset hypogonadism, constitutes the primary commercial barrier identified by GTx.

The broader SARM indication landscape identified in the dataset — hypogonadism, Duchenne muscular dystrophy, osteoporosis, and male contraception — reflects the tissue-selectivity hypothesis’s broad therapeutic potential. Critically, SARMs could theoretically provide anabolic and androgenic benefits (muscle, bone, sexual function) without suppressing the HPG axis, creating a combination niche for hypogonadal men requiring fertility preservation who cannot use exogenous testosterone. According to EMA guidance on androgen receptor modulators, the regulatory pathway for novel tissue-selective agents requires demonstration of both efficacy and absence of prostate safety signals — a dual burden that has slowed SARM clinical advancement.

Gonadotropin-Based Approaches: Clinical Maturity and Fertility Advantage

Gonadotropin therapy — primarily hCG as an LH analog — represents the most clinically established fertility-preserving approach in the male hypogonadism pipeline, with multiple prospective and retrospective series documenting spermatogenesis induction and spontaneous pregnancy rates that exogenous TRT cannot replicate. The critical advantage is mechanistic: LHCGR stimulation on Leydig cells drives endogenous testosterone biosynthesis while preserving the HPG axis feedback loop that maintains spermatogenesis.

The clinical evidence base for hCG spans several distinct patient populations. At the University of Miami Miller School of Medicine, 83.93% of 56 hypogonadic oligozoospermic men responded to weekly subcutaneous hCG (250 μg, approximately 6,500 IU) with improved semen parameters over 3–6 months. A Baylor College of Medicine retrospective review of 52 HH patients compared testosterone versus hCG for pubertal induction, finding hCG therapy associated with testicular growth — a benefit unavailable with testosterone alone. At Chonnam National University, intramuscular hCG (1,500–2,000 IU, three times weekly, 8 weeks) in 20 idiopathic hypogonadotrophic hypogonadism patients with micropenis produced significant testosterone elevation and penile growth.

A separate retrospective multi-institutional US series evaluated hCG monotherapy in men with testosterone above 300 ng/dL but with symptomatic hypogonadism, demonstrating testosterone elevation and symptomatic improvement without TRT — an emerging use case for borderline hypogonadal men where exogenous testosterone would suppress the axis unnecessarily.

Recombinant FSH and Combination Regimens

Recombinant FSH (rFSH) and urinary FSH (uFSH) are used alongside hCG to stimulate spermatogenesis in HH. Istanbul University’s outcomes (85.7% sperm induction, 66.7% pregnancy rates) derive from combined LH/FSH analog replacement. A Shanghai Jiao Tong University multicenter randomised controlled trial (n=67 IHH males) evaluated sequential uFSH/hCG with or without oral zinc supplementation (40 mg/day) as an adjunctive nutrient intervention — a low-cost combination signal with potential accessibility advantages in resource-limited settings.

A patent from La Marca Antonio (Italy, 2022, active) covers a new use of luteinizing hormone, representing a recent IP filing in this space and signalling continued inventor-level innovation in LH-based therapies. The University of Paris-Saclay reported a case of a man with mutant LH-beta subunit producing only 1–2% of normal testosterone yet maintaining complete spermatogenesis — a finding that challenges the dogma of high intratesticular testosterone as a prerequisite for sperm production and has direct implications for the therapeutic threshold design of FSH-dominant regimens in HH. As noted by ESHRE clinical guidelines on male infertility, gonadotropin-based therapy remains the standard of care for HH in fertility-seeking men.

Axis Modulators and Small-Molecule Receptor Agonists: Emerging Oral Alternatives

Four distinct pharmacological strategies exploit the HPG axis to raise endogenous testosterone without suppressing spermatogenesis: SERMs, aromatase inhibitors, pulsatile GnRH, and — most nascently — small-molecule allosteric agonists of LHCGR and FSHR. Together, these approaches define an emerging class of oral or low-burden alternatives to injectable gonadotropin therapy.

SERMs and Aromatase Inhibitors

Clomiphene citrate (CC), a SERM, blocks hypothalamic and pituitary estrogen receptors, disinhibiting LH and FSH secretion and raising endogenous testosterone. A prospective comparative study at Baylor College of Medicine (Houston, n=75) found both CC and testosterone supplementation effective for testosterone normalisation, though CC produced an adverse signal on libido in some men. The University of Leuven’s review of central hypogonadism describes CC and tamoxifen as safe alternatives for functional HH in men not requiring immediate fertility.

Anastrozole (aromatase inhibitor) in obese hypogonadal subfertile men (BMI ≥25 kg/m²) was evaluated retrospectively at Rutgers New Jersey Medical School (n=30), demonstrating FSH increases from 4.8 to 7.6 IU/L, improved motile sperm counts, and clinical pregnancy rates via both IUI and IVF. The Mereo BioPharma 2 Limited patent (Hungary, 2017, active) claims use of the aromatase inhibitor 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile (a letrozole analog) for treating hypogonadism and increasing testosterone levels, including specific dosing regimens and combination formulations — demonstrating that differentiated IP is achievable in this space despite generic competition from clomiphene and anastrozole.

Small-Molecule LHCGR and FSHR Allosteric Agonists

The most nascent modality in the dataset carries the most transformative potential. The I.M. Sechenov Institute of Evolutionary Physiology describes TP4/2, a thieno[2,3-d]pyrimidine-based allosteric agonist of LHCGR, showing comparative effects to hCG on adenylyl cyclase activity and testicular steroidogenesis in young, aging, and diabetic male rats. The mechanistic advantage of allosteric LHCGR agonism is more selective intracellular signalling pathway activation than peptide gonadotropins — potentially reducing off-target effects in aging and diabetic testicular tissue.

From Baylor College of Medicine, oral FSHR allosteric agonists TOP5668 and TOP5300 are in preclinical development, demonstrating appropriate pharmacology, drug metabolism, pharmacokinetics, and safety profiles in Chinese hamster ovary cell assays and animal models. These compounds were designed for ovulation induction, but their FSHR agonist mechanism is directly applicable to hypogonadotropic azoospermia management in men. No clinical trial data have been reported for either compound class. According to WIPO patent trend data, small-molecule receptor agonist filings in the gonadotropin receptor space have increased over the past decade, reflecting growing interest in oral alternatives to injectable peptide hormones.

“Small-molecule oral replacements for injectable gonadotropins — if validated clinically — would represent a paradigm shift in hypogonadotropic hypogonadism management, transforming a complex injection protocol into a daily tablet regimen.”

Pulsatile GnRH and Upstream Axis Stimulation

Pulsatile GnRH therapy directly stimulates pituitary gonadotropin release. A Peking Union Medical College Hospital cohort study of 82 CHH patients receiving subcutaneous pulsatile GnRH identified LH response at 1 month as a predictive marker for spermatogenic outcomes — a clinically useful early signal for treatment responders. Retrieved results from the University of Tennessee also describe KISS1R agonist FTM080 driving LH secretion in vivo in sheep, representing an upstream HPG axis target not yet described in male hypogonadism patents in this dataset but mechanistically relevant to future pipeline development.

Strategic Signals: Where the Pipeline Opportunity Lies

The male hypogonadism drug pipeline presents differentiated opportunity windows across its six therapeutic modalities, with clinical maturity, IP position, and regulatory clarity varying substantially between them. Oral testosterone undecanoate (TLANDO) is the nearest-term commercial opportunity in this dataset, with Phase III-level US clinical data demonstrating efficacy without titration requirements — IP strategists should monitor follow-on formulation patents and combination use claims around oral TU, particularly given the Tongji Hospital data supporting oral TU + hCG co-administration in IHH.

SARMs face an explicitly identified regulatory clarity gap for hypogonadism. GTx results identify the absence of defined clinical endpoints for late-onset hypogonadism as a commercial barrier to SARM registration, despite compelling preclinical and early clinical data. Developers should track FDA guidance on patient-reported outcomes and functional endpoints in this indication. The SARM-2f data from Takeda — EC50 of 3 nmol/L for monkey AR, lean body mass increases, and lipid reduction over 4 weeks with no prostate stimulation — represent the most pharmacologically advanced preclinical profile in the dataset for a non-GTx SARM program.

hCG and gonadotropin therapy occupies a defensible niche for fertility-seeking hypogonadal men that exogenous TRT cannot address. Retrieved clinical data demonstrate high spermatogenesis induction rates and spontaneous pregnancy outcomes (66.7% at Istanbul University, n=112). Subcutaneous self-administration formulations and long-acting gonadotropin analogs represent incremental innovation opportunities in this space. The La Marca Antonio Italian patent (2022, active) on new uses of luteinizing hormone signals continued inventor-level IP activity.

Small-molecule LHCGR and FSHR allosteric agonists are strategically significant but entirely early-stage: TP4/2 (I.M. Sechenov Institute) and TOP5668/TOP5300 (Baylor College of Medicine) are the only named compounds in the dataset. Freedom-to-operate and IP landscaping in the thieno[2,3-d]pyrimidine chemical space warrants attention as these programs advance. If validated clinically, oral replacements for injectable gonadotropins would represent a paradigm shift in HH management — transforming a complex injection protocol into a daily tablet regimen. Tools such as PatSnap Eureka enable drug discovery teams to monitor this chemical space in real time, identifying new filings and freedom-to-operate risks before they become competitive threats. The PatSnap platform aggregates over 2 billion data points across 120+ countries, providing the breadth required to track a globally distributed pipeline of this complexity.